Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer
Etienne Auvert, Emmanuel Douez, Louis Jolivet, Tiffany Witkowski, Anne-Catherine Jallas, Fanny Boursin, Ioana Molnar, Cyril Colas, Sandrine Valsesia Wittmann, Manon Auriol, Jean‐Michel Chezal, Nicolas Aubrey, Émilie Allard-Vannier, Aurélie Maisonial‐Besset, Nicolas Joubert, Caroline Denevault‐Sabourin
Abstract
High Resolution Image Download MS PowerPoint Slide The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has significantly improved with the advent of anti-HER2 therapies, especially antibody-drug conjugates (ADCs). In this field, ADCs, like trastuzumab deruxtecan (T-DXd), using camptothecin analogs, represent a promising strategy. However, T-DXd can induce resistance and serious adverse effects, potentially driven by a non-specific Fcγ receptor-mediated endocytosis. Here, we report the development of novel HER2-targeting conjugates, using the camptothecin derivative exatecan and a linker optimized to control hydrophobicity. Three formats were evaluated: a high drug-to-antibody ratio (DAR) 8 IgG-based ADC (IgG(8)-EXA), and two DAR 4 Fc-free constructs (Mb(4)-EXA and Db(4)-EXA). Thus, IgG(8)-EXA and Mb(4)-EXA displayed potent, specific cytotoxicity against HER2-positive breast cancer cells and strong antitumor activity in vivo . Notably, IgG(8)-EXA exhibited a favorable pharmacokinetic profile, despite its high DAR, supporting the potential of this drug-linker design. These two conjugates represent promising candidates for further preclinical development.